Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'

Ann Oncol. 2017 Dec 1;28(12):3101-3103. doi: 10.1093/annonc/mdx533.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin*
  • Carcinoma, Non-Small-Cell Lung
  • Cisplatin
  • Etoposide*
  • Humans
  • Lung Neoplasms
  • Neoplasm Staging
  • Paclitaxel
  • Survival Analysis

Substances

  • Etoposide
  • Carboplatin
  • Paclitaxel
  • Cisplatin